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INTRODUCTION 
Solubility is an important criterion for drug efficacy, 
independent of route of administration. It also poses a 
major challenge for pharmaceutical industries, which are 
developing new pharmaceutical products, since 40% of 
the active substances being identified are either insoluble 
or poorly soluble in aqueous media1. A limiting factor 
for in vivo performance of poorly water soluble drugs, 
following oral administration, is their resistance to being 
wetted and being dissolved into the fluid in the 
gastrointestinal tract1. Increasing the dissolution rate of 
poorly water soluble drugs is thus important for 
optimizing bioavailability1. To overcome these problems, 
various formulation strategies are reported in the 
literature including the use of surfactants (e.g. tween 80, 
gelucire), cyclodextrins (e.g. beta-cyclodextrin, 
hydroxypropyl beta-cyclodextrin), solid dispersions, 
micronization, lipid based systems2,3,4,5. However, these 
approaches are successful in only selected cases. 
Nanoparticles are defined as particulate dispersions or 
solid particles with a size in the range of 10-1000 nm6. 
Nanocapsules are systems in which the drug is confined 
to a cavity surrounded by a unique polymer membrane, 
while nanospheres are matrix systems in which the drug 
is physically and uniformly dispersed6. Glibenclamide is 
one of the most widely used anti hyperglycemic drug. 
However, glibenclamide’s low bioavailability has been 
attributed to its poor dissolution properties7. Hence, in 
the study it is planned to formulate polymeric 
nanoparticles of Glibenclamide to improve its dissolution 
and absorption. 
 
METHODS 
Preparation of polymeric nanoparticles of 
glibenclamide: 
Weighed amount of drug was dissolved in 
dichloromethane, and weighed amount of Eudragit 
RLPO polymer was dissolved in methanol (Table 1). 
Drug-polymer solution was prepared by mixing the 
solutions, followed by vortexing. The drug-polymer 
solution was homogenized at 10000-13000 rpm and 
sonicated. The solution was then evaporated using a 
rotary evaporator, until there were no traces of the 
organic solvent. The resulting solution was centrifuged 
and the solution was freezed at -800C and then 
lyophilized, after the addition of required quantity of 
mannitol.  
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ABSTRACT  
Simple, reliable and reproducible method was used for the preparation of polymeric nanoparticles of Glibenclamide. The 
formulation was prepared by solvent evaporation method using magnetic stirrer with overnight stirring and the same was then 
evaluated for its particle size, drug content and in vitro dissolution studies. The above mentioned method showed similar 
particle size and exhibited an improvement in the drug entrapment efficiency. The ultraviolet spectrophotometric method was 
used to analyze Glibenclamide at 300 nm in different buffers. The study demonstrated the successful preparation of sustained 
release polymeric nanoparticles of Glibenclamide. 
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Table 1: Formulation of various batches of polymeric nanoparticles 
 
Ingredient 
Drug polymer ratio 
1:5 1:10 1:20 1:40 
Drug(mg) 5 5 5 5 
Polymer(mg) 25 50 100 200 
 
 
Optimized batches of the ratios 1:5 and 1:40 were 
prepared using the same procedure stated above. 
Evaluation of polymeric nanoparticles: 
Particle size 
The particle sizes of the different formulations were 
measured using Malvern Zeta Sizer (Nano ZS), before 
and after lyophilization.  
Drug content 
5mg of the lyophilized sample of each of the optimized 
formulations was weighed, dissolved in 5ml of the 
methanol, and the absorbance was measured 
spectrophotometrically at 300 nm. The percentage 
entrapment was calculated.  
In vitro release 
The dissolution study was carried out using Type 2 
dissolution with 900ml of phosphate buffer (pH 6.8) for 
6 hours, first at intervals of 30 minutes, and then at 
intervals of an hour. The dissolution medium was kept in 
a thermostatically controlled water bath, maintained at 
37 ±0.50 C. The pre-weighed formulation was filled in a 
capsule, and then introduced into the dissolution jar. The 
paddle was rotated at 75rpm. At different time intervals 
the samples were withdrawn and analyzed 
spectrophotometrically at 300nm for drug release.  
RESULTS AND DISCUSSION 
Particle size 
The particle sizes of the formulations were measured 
before and after lyophilization, and the results showed 
that particles were within the desired size range (Table 
2,3). 
  
 
Table 2: Particle size of formulations 
 
Drug polymer ratio 
Particle size(nm) 
Before lyophilization After lyophilization 
1:5 154 2929 
1:10 95.4 2793 
1:20 100.4 1267 
1:40 133 1503 
 
Table 3: Particle size for Optimized Formulations 
 
Drug polymer ratio 
Particle size(nm) 
Before lyophilization After lyophilization 
1:5 741.6 626.2 
1:40 554.5 683.6 
 
 
Drug content  
The drug content of the optimized formulations was 
calculated, after measuring the absorbance at wavelength 
300nm. The drug content of the formulation had a 
percentage entrapment in the range of 50-60%. 
In vitro drug release 
Drug release profile of 1:4 and 1:5 drug polymer ratios 
was calculated. Dissolution study was performed for 1:4 
and 1:5 drug polymer ratio and percentage cumulative 
drug release was calculated (%CDD). The drug polymer 
ratio showed an increase in drug release with time. 
Formulation exhibited a complete drug release at the end 
of 6hrs (Figure 1) 
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Figure 1: Drug release profile 
 
 
CONCLUSION 
The drug Glibenclamide was prepared by solvent 
evaporation   method using magnetic stirrer with 
overnight stirring and the nanoparticles produced were 
evaluated. The optimized formulation prepared showed 
similar particle sizes and exhibited an improvement in 
the drug entrapment efficiency. Formulation exhibited a 
complete drug release at the end of 6hrs. The present 
study demonstrated the successful preparation of 
sustained release polymeric nanoparticles of 
Glibenclamide.
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